anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Oropharyngeal microbiomes play a significant role in the susceptibility and severity of COVID-19, yet the role of these microbiomes play for the development of COVID-19 Omicron variant have not been reported. A total of 791 pharyngeal swab samples were prospectively included in this study, including 297 confirmed cases of Omicron variant (CCO), 222 confirmed case of Omicron who recovered (CCOR), 73 confirmed cases of original strain (CCOS) and 199 healthy controls (HC). All samples completed MiSeq sequencing. The results showed that compared with HC, conditional pathogens increased in CCO, while acid-producing bacteria decreased. Based on six optimal oropharyngeal operational taxonomy units (OTUs), we constructed a marker microbial classifier to distinguish between patients with Omicron variant and healthy people, and achieved high diagnostic efficiency in both the discovery queue and the verification queue. At same time, we introduced a group of cross-age infection verification cohort and Omicron variant subtype XBB.1.5 branch, which can be accurately distinguished by this diagnostic model. We also analyzed the characteristics of oropharyngeal microbiomes in two subgroups of Omicron disease group-severity of infection and vaccination times, and found that the change of oropharyngeal microbiomes may affect the severity of the disease and the efficacy of the vaccine. In addition, we found that some genera with significant differences gradually increased or decreased with the recovery of Omicron variant infection. The results of Spearman analysis showed that 27 oropharyngeal OTUs were closely related to 6 clinical indexes in CCO and HC. Finally, we found that the Omicron variant had different characterization of oropharyngeal microbiomes from the original strain. Our research characterizes oropharyngeal microbiomes of Omicron variant cases and rehabilitation cases, successfully constructed and verified the non-invasive diagnostic model of Omicron variant, described the correlation between microbial OTUs and clinical indexes. It was found that the infection of Omicron variant and the infection of original strain have different characteristics of oropharyngeal microbiomes.
Osteoarthritis (OA) is among the most prevalent chronic, disabling conditions, occurring in over 32 million persons in the US. Worldwide, an estimated 240 million persons have symptomatic, activity-limiting OA. OA cases arising from injury are referred to as post-traumatic OA (PTOA). Approximately 12% of cases of lower extremity symptomatic OA are PTOA, often the result of injuries such as anterior cruciate ligament (ACL) rupture or ankle fracture. Four million Americans have PTOA. On average, patients with PTOA develop knee OA 10.4 years earlier than those with primary knee OA. Similarly, individuals with PTOA of the hip and ankle develop OA 9.0 and 14.0 years, respectively, earlier than their primary OA counterparts. Sustaining ACL injury early in adulthood leads to greater lifetime risk as well as earlier onset of knee OA and need for total knee replacement (TKR). The earlier age of onset means that PTOA is often a disorder of working persons, compromising productivity and quality of life. The indirect cost burden of PTOA is estimated to be \~$4.4 billion annually, because individuals are typically affected in their most productive years of employment.

Anterior cruciate ligament (ACL) injury is the most common sports-related knee injury, and many patients who wish to return to sporting activities that involve cutting and pivoting will choose to undergo ACL reconstruction (ACLR). Each year, more than 120,000 ACL reconstructions are performed in the US alone. Even though ACLR can allow people to return to sporting activities with a stable knee, there is still an increased risk of PTOA after the ACL injury and subsequent reconstruction. Studies have demonstrated that around 50% of patients who undergo ACL reconstruction develop OA within 10-15 years. Given the large number of ACL injuries and subsequent reconstructions that occur annually, and the strong association between ACL tear/reconstruction and PTOA, developing treatment strategies to delay or prevent PTOA and promote long-term health after ACLR is critical to maintaining the well-being of young, active populations. This study proposes to address these issues by testing the efficacy of metformin, a commonly used and safe drug with promising pre-clinical and clinical evidence of PTOA prevention, in younger adults undergoing ACL reconstruction.

PIKASO is a multicenter, double-blind (participants, treating clinicians, and assessors), placebo-controlled, randomized study to establish the efficacy of metformin at delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament reconstruction. Subjects will be randomized in a 1:1 ratio. Each subject will complete standard-of-care postoperative physical therapy in both arms. The two primary outcomes will be KOOS pain (assessed at 12 and 24 months postoperatively and averaged) and modified MRI Osteoarthritis Knee Score (MOAKS) cartilage score at 24 months postoperatively.
The 3.1 target of the Sustainable Development Goals of the United Nations aims to reduce the global maternal mortality ratio to less than 70 maternal deaths per 100,000 live births by 2030. The last updates on this target show a significant stagnation in the data, thus reducing the chance of meeting it. What makes this negative result even more serious is that these maternal deaths could be avoided through prevention and the wider use of pharmacological strategies and devices to stop postpartum haemorrhage (PPH). PPH is the leading obstetric cause of maternal mortality in low- and middle-income countries (LMICs). Despite low-cost devices based on the uterine balloon tamponade (UBT) technique are already available, they are not safe enough to guarantee the complete stop of the bleeding. When effective, they are too expensive, especially for LMICs. To address this issue, this study presents the design, mechanical characterisation and technology assessment performed to validate a novel low-cost UBT kit, particularly a novel component, i.e., the connector, which guarantees the kit's effectiveness and represents the main novelty. Results proved the device's effectiveness in stopping PPH in a simulated scenario. Moreover, economic and manufacturing evaluations demonstrated its potential to be adopted in LMICs.
Diseases including hypertriglyceridemia, diabetes, impaired glucose tolerance, obesity and fatty liver are composite syndromes defined as life style-related diseases. It appears that the fundamental cause for these diseases resides in hypermetabolism of fatty acids in the liver or fat tissues due to the accumulation of visceral fat. It is considered that accelerated fatty acid synthesis ability can be generally ameliorated by inhibiting the effect of SREBP-1c which is a transcriptional factor comprehensively controlling the lipogenic enzyme family. Thus, it is expected that fatty acid synthesis can be more efficiently lowered thereby. A novel tricyclic compound or a pharmaceutically acceptable salt thereof which has effects of lowering the triglyceride level in the liver and lowering the blood glucose level by inhibiting the expression of SREBP-1c and, therefore, is useful as a preventive or a remedy for diabetes, hyperlipemia, fatty liver, obesity, impaired glucose tolerance, diabetic complications (for example, nephropathy, nervous disorder, retinopathy, etc.), metabolic syndrome and syndrome X.
The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
Commercially available Acamprosate 333 mg tablets will be administered three times daily. Subjects will be started with one tablet with breakfast for 3 days, then one tablet with breakfast and dinner for 3 days, then one tablet 3 times a day for the next 15 days. Intervention order of medication trials will be determined by biostatistician.
Participants will be assessed using ESAS, ENP and adhoc sociofamiliar questions just before entering their Phase I Clinical Trial (T0). Responses of this assessment will be discussed in a multidisciplinary committee comprised of a palliative physician, a clinical psychologist, a social worker, an oncologist, an hematologist and the Phase 1 Unit referent nurse. According to the patient responses, the committee will decide which needs will be addressed and this will be cited to the corresponding professional (palliative, psychologist and/or social worker) within the following 15 days. The same cycle (assessment - committee - attention) will take place a month after the T0 (T1), and during the following 2 other months (T2 and T3).
This study aimed to establish sex- and age-specific reference values for motor performance (MP) in Hong Kong preschoolers aged 3-5 years old and examine the relationship between MP and BMI status. A cross-sectional study was conducted among 5579 preschoolers in Hong Kong. Three MP tests were administered, and height and weight information were collected. GAMLSS was used to compute the normative values of the motor tests. Boys outperformed girls in activities requiring muscle strength and power, while girls outperformed boys in activities requiring balance and coordination. The MP scores increased with age for both overarm beanbag throw and standing long jump for both sexes, while the one-leg balance scores showed larger differences between P50 and P95 in older preschoolers. Children with excessive weight performed worse in standing long jump and one-leg balance compared to their healthy weight peers. This study provides valuable information on the MP of preschoolers in Hong Kong, including sex- and age-specific reference values and the association between BMI status and MP scores. These findings can serve as a reference for future studies and clinical practice and highlight the importance of promoting motor skill development in preschoolers, particularly those who are overweight or obese.
Most studies agree that anxiety disorders are more frequent in people with intellectual disabilities that in the general population. Williams syndrome (WS) is a rare disease, associated with an anxiety rate 8 times higher than in the general population. The therapeutic solutions proposed in this population remain limited, in particular concerning approaches without the use of medication. The objective of the study is to evaluate the effectiveness of a program of Cognitive and Behavioral Therapies (CBT) in Williams Syndrome (WS). For this, an ABA-type protocol will be used. It consists of evaluating the effectiveness of an interventional program longitudinally, using a single case type study. Adults patients with WS and suffering from anxiety will be recruited. They will be enrolled in a program consisting in nine sessions of a psychotherapy program targeting anxiety. There will be a pretherapy visit (day 0), nine sessions of psychotherapy (month 0 to month 5) and a visit 3 month after the end of the therapy (at month 8) : the visit of the end of the research (V10). The expected results will be to validate a psychotherapeutic program for patients with WS suffering of anxiety. This program might be extended to other patients with intellectual disability.
The objective of this retrospective study was to investigate the impact of tourniquet use during intramedullary tibial nailing on clinical outcomes at a regional Level I Trauma Center. One hundred ninety-four patients with intramedullary tibial fixation over a 5-year period at a single institution were studied following Institutional Review Board (IRB) approval. Patients were stratified into 81 polytrauma patients and 113 patients with isolated tibial shaft injuries. Patients were then stratified within these two groups according to whether or not a tourniquet was used intraoperatively (including during reaming). Postoperative narcotic use, length of stay, operating room (OR) time, tourniquet time, estimated blood loss, units of blood utilized, infection rate, and age were the outcome variables. No significant differences were found for any outcome measure (p ≥ 0.05), including age, narcotic use, OR time, postoperative inpatient days, estimated blood loss, and units of blood used between tourniquet and nontourniquet patients. Statistically significant differences were found between isolated and nonisolated fracture patients for postanesthesia care unit (PACU) morphine dose equivalents (MDEs), with isolated tibia fracture patients requiring more MDEs (13.80 vs. 9.92 units; p = 0.025). Nonisolated tibia patients had more inpatient days (14.88 vs. 3.16 days; p = 0.001), greater estimated blood loss (252.44 vs. 128.07 mL; p = 0.001), and more units of blood (5.07 vs. 2.29 units; p = 0.017). Thermal necrosis of the tibia was not seen in any patient within any group. Tourniquet use did not significantly affect clinical outcomes. This provides surgeons with updated data on the impact of tourniquet use on clinical outcomes given the modernization of techniques for tibial intramedullary nailing. There were statistically significant differences between isolated tibia fractures and polytrauma patients for postoperative length of stay, estimated blood loss, and units of blood; however, this was unrelated to tourniquet use and would be expected for polytraumatic patients who commonly have a longer postoperative recovery. (Journal of Surgical Orthopaedic Advances 33(3):181-183, 2024).
In five randomized, double-blind clinical trials of 1,319 subjects, 397 used clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%, 396 used benzoyl peroxide, 349 used clindamycin, and 177 used vehicle. Subjects were instructed to wash the face, wait 10 to 20 minutes, and then apply medication to the entire face, once daily in the evening before retiring. Clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% applied once daily for 11 weeks was significantly more effective than vehicle, benzoyl peroxide, and clindamycin in the treatment of inflammatory lesions of moderate to moderately severe facial acne vulgaris in three of the five trials (Trials 1, 2, and 5). Subjects were evaluated and acne lesions counted at each clinical visit at Weeks 2, 5, 8, 11.

The primary efficacy measures were the lesion counts and the investigator's global assessment evaluated at Week 11. Percent reductions in inflammatory lesion counts after treatment for 11 weeks in these 5 trials are shown in Table 2.

The group treated with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% showed greater overall improvement in the investigator's global assessment than the benzoyl peroxide, clindamycin, and vehicle groups in three of the five trials (Trials 1, 2, and 5).

Clinical trials have not adequately demonstrated the effectiveness of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% versus benzoyl peroxide alone in the treatment of non-inflammatory lesions of acne.
ABSTRACT The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, a citrate buffering agent/system such as .. sodium citrate/citric acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug. Date Recue/Date Received 2021-01-05
The invention relates to a novel composition which combines defined proportions of a soluble saccharide which is poorly absorbed by the organism (the most widely known being disaccharides such as lactulose, lactitol, trehalose) and an antiflatulent from the siloxane group (the most widely known being polydimethylsiloxanes such as simeticone, dimeticone). The inventive composition takes the form of a medicament or nutriceutical which is essentially intended to treat constipation without causing the adverse digestive effects such as meteroism and flatulence associated with poorly-absorbed soluble saccharides. The composition is also intended for the regeneration of intestinal flora and for the symptomatic treatment of functional digestive disorders involving bloating and constipation. The antiflatulent/saccharide ratio can be varied in order to produce essentially-laxative compositions with low ratios and essentially-antiflatuelnt compositions with higher ratios. Moreover, the ratio can be varied within the range of low ratios in order to produce different formulations which are intended for the initial and maintenance treatment of constipation. The novel composition can also comprise one or more excipients and/or one or more other active principles and can take the form of a stabilised liquid or a solid.
The invention discloses a pharmacy rational medication rule checking service system based on a knowledge base. The invention comprises a medical insurance medicine purchasing terminal module, a medical insurance reasonable medicine service module and a medical insurance reasonable medicine knowledge base. The medical insurance purchasing terminal module is used for performing medical insurance settlement on purchased medicines; the medical insurance reasonable medication service module comprises a receiving unit, a reasonable medication processing unit and a sending unit; the medical insurance reasonable medication knowledge base comprises a maintenance unit and a storage unit of the knowledge base. The invention provides reasonable medicine use auxiliary inspection for pharmacists by providing reasonable medicine use inspection service for the medical insurance settlement system. And a pharmacist invokes the service in the process of selling and settling the medical insurance, so that the examination efficiency is improved, and illegal medication is reduced. The medical insurance reasonable medication knowledge base can be expanded and perfected according to the latest national rules.
Disclosed are deep-learning-based intelligent pneumonia diagnosis system and method for X-Ray chest radiograph, belonging to the technical field of medical image classification. The system comprises a user login and registration module, a picture format conversion module and a pneumonia prediction module; and by means of a B/S architecture, the system is divided into four layers, i.e. a platform layer, a support layer, a service layer and an application layer. An installation process performed by a user is simple, and dependence on a local environment is reduced. By means of a friendly interface and system modules which are designed according to actual requirements, the present system is enabled to be functionally fused with other systems. In the deep-learning-based intelligent pneumonia diagnosis method for X-Ray chest radiograph, means such as data enhancement, transfer learning and network structure improvement accelerate the convergence rate of model training, and improve the accuracy rate of pneumonia recognition and the generalization capability of a model. Confusion caused to doctors by manual radiograph viewing can be greatly reduced.
According to the present disclosure it has been found that the administration of an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold may reduce considerably the risk of mortality in a patient having a severe chronical or acute disease. In a preferred embodiment of the present disclosure said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds to a region of ADM that is located in the N-terminal part (aa 1-21) of adrenomedullin, (see  Fig. 2 ). In another preferred embodiment said anti-ADM antibody or anti-ADM fragment or anti-ADM non-Ig scaffold recognizes and binds to the N-terminal end (aa1) of adrenomedullin. N-terminal end means that the amino acid 1, that is "Y" of SEQ ID No. 21 or 23, is mandatory for antibody binding. The anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold would neither bind N-terminal extended nor N-terminal modified Adrenomedullin nor N-terminal degraded Adrenomedullin in said preferred embodiment.
Participants randomized to the CBT condition will receive access to a pain self-management program, available through any internet-enabled device. The design and treatment content follow a cognitive-behavioral framework in which participants receive information to understand their CP pain, learn a range of cognitive and behavioral skills to manage their symptoms and difficulties, and practice and adopt the skills taught in the program. The program consists of 5 online lessons, which are in the form of a slide show, and 5 downloadable lesson summaries, which provide homework assignments to assist participants in learning and applying the skills described in the lessons. These materials are released over the course of eight weeks and include a combination of didactic information and narrative examples. Several detailed case stories and real-world examples of individuals with CP pain are integrated throughout the course.
1,180,570. Abrasion - resistant colourless granulates. ARZNEIMITTELWERK DRESDEN VEB. 8 May, 1967, No. 21220/67. Addition to 1,088,777. Heading C2C. Abrasion-resistant colourless granulates of solid pharmaceutical substances (i.e. any substance which is known and used medicinally) other than caffeine, are obtained by a process which comprises melting said substance in the presence of a reducing agent which is chemically inert to said substance and which completely leaves the melt by the time the melt has cooled and the melt obtained is either (a) atomized before cooling; or (b) after cooling is broken to the required particle size. The reducing agent may be, for example, formaldehyde, hydrazine, aqueous formic acid or a salt of formic acid and may be present in an amount of from 0.01 to 10 mol. per cent referred to the amount of substance used. The reducing agent may also be used as a solution, e.g., using water or an inert organic solvent and an inert gas such as nitrogen may also be utilized. The examples describe the granulation of phenobarbital, aminophenazone and phenacetin.
The present invention provides a medicine for treating acute bacillary dysentery and acute enteritis, which has the advantages of high efficiency, little toxic and side effect, and low price. The medicine for treating acute bacillary dysentery and acute enteritis is prepared from the main drugs of the proportion by weight: 5 to 9 portions of humifuse euphorbia herb and 3 to 6 portions of european verbena. As the improvement, baical skullcap root can be used as supplementary drug, or flaccid knotweed herb is used as the auxiliary drug. The medicine for treating acute bacillary dysentery and acute enteritis can be prepared into any normal oral preparation by using the normal method for Chinese drug preparations. The clinical practice proves that The medicine for treating acute bacillary dysentery and acute enteritis can be used for treating diseases, such as digestive system infection, urinary infection, bleeding, etc., with high therapeutic effect, short treatment course and low price; in addition, the present invention does not have obvious adverse reaction, or toxic and side effect. The present invention has favorable effect for treating bacillary dysentery, acute enteritis, urinary tract infection, bleeding, etc.